Literature DB >> 12005403

Management of tumor bed cysts after chemotherapeutic wafer implantation. Report of four cases.

Matthew J McGirt1, Alan T Villavicencio, Ketan R Bulsara, Henry S Friedman, Allan H Friedman.   

Abstract

Adjuvant use of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) wafers with surgical resection is becoming common for the treatment of malignant gliomas. Cyst formation in the tumor resection cavity is a recently described complication associated with the use of BCNU wafers. There is currently no report in which successful management of this complication without additional surgical intervention is described. The authors describe four patients in whom postoperative cysts developed in the tumor resection cavity after placement of BCNU wafers. These include a 38-year-old man with a left frontoparietal tumor, a 48-year-old man with a right frontal lobe tumor, a 78-year-old man with a left parietooccipital tumor, and a 61-year-old woman with a left frontotemporal tumor. Histopathological studies of biopsy samples revealed malignant glioma in each patient. All four patients had unremarkable perioperative courses, were discharged within 3 to 8 days of surgery, and subsequently returned with acute neurological deterioration. Follow-up magnetic resonance (MR) imaging demonstrated cyst formation with significant mass effect at the previous resection site. Three patients were treated with high-dose dexamethasone and returned to their neurological baseline over an 8-day period. The fourth patient improved after surgical drainage and biopsy sampling of the cyst, which revealed no evidence of infection or recurrent tumor, but again sought medical care 2 weeks later with cyst recurrence necessitating high-dose steroid therapy. On MR images at least a 30% reduction in cyst size was demonstrated in all four patients, each of whom remained clinically stable at 2, 6, 6, and 4 months of follow-up review. Neurosurgeons should be aware of the potential for postoperative cyst formation accompanied by clinically significant mass effect after BCNU wafer implantation, as well as the potential for successful nonsurgical management leading to clinical and radiological improvement.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12005403     DOI: 10.3171/jns.2002.96.5.0941

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  13 in total

1.  Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

Authors:  Stephan Ulmer; Klara Spalek; Arya Nabavi; Susan Schultka; H Maximillian Mehdorn; Santosh Kesari; Lutz Dörner
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

Review 2.  Neurosurgical oncology: advances in operative technologies and adjuncts.

Authors:  Randy S D'Amico; Benjamin C Kennedy; Jeffrey N Bruce
Journal:  J Neurooncol       Date:  2014-06-27       Impact factor: 4.130

3.  Incorporating BCNU wafers into malignant glioma treatment: European case studies.

Authors:  Anne Balossier; Lutz Dörner; Evelyne Emery; Oliver Heese; H Maximilian Mehdorn; Philippe Menei; Jagmohan Singh
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

4.  Sustained radiographic and clinical response in patient with bifrontal recurrent glioblastoma multiforme with intracerebral infusion of the recombinant targeted toxin TP-38: case study.

Authors:  John H Sampson; David A Reardon; Allan H Friedman; Henry S Friedman; R Edward Coleman; Roger E McLendon; Ira Pastan; Darell D Bigner
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

5.  Discriminating surgical bed cysts from bacterial brain abscesses after Carmustine wafer implantation in newly diagnosed IDH-wildtype glioblastomas.

Authors:  Alexandre Roux; Hichem Ammar; Alessandro Moiraghi; Sophie Peeters; Marwan Baroud; Gilles Zah-Bi; Joseph Benzakoun; Eduardo Parraga; Catherine Oppenheim; Chiara Benevello; Fabrice Chretien; Pascale Varlet; Frédéric Dhermain; Edouard Dezamis; Marc Zanello; Johan Pallud
Journal:  Neurosurg Rev       Date:  2021-10-14       Impact factor: 3.042

6.  Evaluation of serial changes on computed tomography and magnetic resonance imaging after implantation of carmustine wafers in patients with malignant gliomas for differential diagnosis of tumor recurrence.

Authors:  Shiro Ohue; Shohei Kohno; Akihiro Inoue; Daisuke Yamashita; Satoshi Suehiro; Toshimoto Seno; Yoshiaki Kumon; Keiichi Kikuchi; Takanori Ohnishi
Journal:  J Neurooncol       Date:  2015-09-18       Impact factor: 4.130

Review 7.  The combination of carmustine wafers and temozolomide for the treatment of malignant gliomas. A comprehensive review of the rationale and clinical experience.

Authors:  A Gutenberg; C B Lumenta; W E K Braunsdorf; M Sabel; H M Mehdorn; M Westphal; A Giese
Journal:  J Neurooncol       Date:  2013-03-28       Impact factor: 4.130

8.  Reoperation as a result of raised intracranial pressure associated with cyst formation in tumor cavity after intracranial tumor resection: a report of two cases.

Authors:  Jinlu Yu; Wenji Xiong; Limei Qu; Haiyan Huang
Journal:  Case Rep Med       Date:  2010-09-28

9.  Safety and efficacy of concomitant chemotherapeutic wafers and iodine-125 seeds for recurrent glioblastoma.

Authors:  Andrew L Ko; Kathleen R Fink; Keith M Stelzer; Daniel L Silbergeld
Journal:  Surg Neurol Int       Date:  2012-11-20

10.  Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Authors:  Daniela A Bota; Annick Desjardins; Jennifer A Quinn; Mary L Affronti; Henry S Friedman
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.